| 17-1493 | Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS Metastasis | Open (affiliates only) |
| A011502-CIRB-REX | Rex_Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial | Open (affiliates only) |
| A031102-CIRB | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors | Open |
| AGCT1531 | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | Open |
| AMGEN359 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of
Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of
Recurrence (D-CARE) | Open (affiliates only) |
| AMGEN482 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With
Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly
Diagnosed Multiple Myeloma | Open (affiliates only) |
| ANBL1531 | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | Open |
| ANHL1522 | A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| ASG-22CE-13-2 | A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 | Open |
| BMT-CTN-1506 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | Open |
| CP-MGD014-01 | A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | Open |
| DF-HCC17101-PACE | DF-HCC 17-101: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (Protocol #: 17-101) | Open |
| E4412-CIRB | A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma | Open |
| EAY131-A | MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment | Open |
| ETCTN9767-CIRB | An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation. | Open |
| FADOI03-2016 | Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio Study | Open |
| GU15-262 | Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | Open |
| LCCC1907-ATL-COM | Compassionate Use Re-Infusion of ATLCAR.CD30 | Open |
| NCI-CT018-10129-CIRB | A Phase 2 Study of PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | Open |
| ODO-TE-B301 | A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane | Open |
| ONC012 | A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer | Open |
| PANTHER | PANTHER: Prospective study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy Naïve mEn with mCRPC Stratified by Race (PANTHER) | Open |
| RTOG1008 | A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Open |
| S1702-CIRB | S1702, CIRB " A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated Al Amyloidosis | Open |
| SGN22E-002 | A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer | Open |
| UAZ2016-08-02 | A Phase I safety and dose-finding trial of alternate-weekly, self-administered, intravaginal application of 5-fluorouracil and imiquimod for treatment of high-grade cervical intraepithelial lesions | Open |
| UC13-0540 | Afatinib in advanced refractory urothelial cancer | Open |